{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-010211","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.187683+00:00","generated_at":"2026-05-24T01:35:12.872123+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025","bullets":["Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.","Cash and investments $90.1M at Dec 31, 2024, down $81.7M from year-end 2023; $42.7M cost outlays.","OMIDRIA royalties Q4 $10.1M on Rayner sales $33.6M, up from $9.3M on $31.0M in Q3.","BLA for narsoplimab in TA-TMA resubmitted to FDA Mar 2025; PDUFA target September 2025.","Phase 3 for zaltenibart in PNH initiated; NIDA awarded $4.02M for OMS527 CUD study; data readout by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-010211","json":"https://secwatch.observer/filing/0001437749-25-010211.json","markdown":"https://secwatch.observer/filing/0001437749-25-010211.md","text":"https://secwatch.observer/filing/0001437749-25-010211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/0001437749-25-010211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/omer20241119_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:35:12.872123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}